The concept of a "passport" is changing due to COVID-19. Conventionally, a passport is an official document issued by a government agency to certify identity and citizenship, as well as authorizing travel. "Golden passports" have been sought after by the wealthy as a method to gain citizenship-by-investment in regions of the world that have advantageous tax structures (Shachar [@CR14]). In the era of COVID-19, antibodies (proteins made by the immune system to fight infection) are posed as a form of currency that can permit "certified" individuals to return to work or travel (see, for example, Bartlett [@CR1]). In this way, antibodies for SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2---the COVID-19 coronavirus) are potentially the new golden passport, but the concept is a moving target with clinical unknowns, as well as legal and ethical complexity (Phelan [@CR13]; Persad and Emanuel [@CR12]).

Research and innovation normally move at the pace of a marathon, but during a pandemic the pace is more like a sprint, creating an environment which is ripe for human error, as well as research and business misconduct, amid a sea of scientific uncertainty, anxious patients and families, and economic frailty (Bramstedt [@CR2]). In the United States, at least 160 types of antibody test kits have been available; however, due to limited regulatory assessment in the race to release product, these have questionable performance (Burton [@CR4]). Sensitivity and specificity performance thresholds are now set (U.S. Food and Drug Administration [@CR15]), and the results are catalogued in an open access format (U.S. Food and Drug Administration [@CR16]). Yet even with a robust quality standard and improved regulatory screening of test kits, there remains more questions to address.

At-Home Testing {#Sec1}
===============

Home testing for the identification of SARS-CoV-2 RNA \[active infection\] is already available in the United States (U.S. Food and Drug Administration [@CR17]). This permits symptomatic people \[patients\] to self-swab with a home collection kit, sending their nasal swab sample via priority shipping to the approved laboratory for analysis. Kits are registered online with a twelve-digit barcode that links the patient to the collection tube. Positive results are reported to the patient and the public health authority. Positive results can facilitate a clinical treatment plan, but what is the role of negative results? How long does the negative result last and when should such patients be retested? These questions about negative results are important because there can be a window of time during which patients (with and without symptoms) are infected and potential vectors of the disease. Also, knowing the true source of the sample is vital; this is not necessarily the name of the person linked to the barcode. There are many ways to fake an identity, but genetic linking can give true identity. However, the associated patient documents for the RNA home test do not mention any provision for genetic testing to identify the sample owner (LabCorp [@CR10], [@CR11]).

Currently, COVID-19 antibody testing requires an in-person visit for blood sampling in the inpatient or outpatient setting. This in-person visit allows for personal identification verification of the sample provider. If COVID-19 antibody testing evolves to the home setting using a finger-stick blood sample, the issue of identity verification emerges (Brown [@CR3]). This is because the perceived social and economic value of a positive antibody result is significant, and fraudulent sampling can occur with ease (for example, submission of a sample from someone already confirmed to be COVID-19 antibody positive). Without verification of the true owner of the antibody specimen, identify theft could be a new problem of this pandemic.

Fraudulent Certifications/Passports {#Sec2}
===================================

With the COVID-19 pandemic causing a fragile worldwide economy and millions of people unemployed (Congressional Research Service [@CR6]), there is a risk of antibody certificates being viewed as the "golden passport" to return to work and travel. The WHO (World Health Organization [@CR18]) has stated the presence of SARS-CoV-2 antibodies is not a guarantee that a person cannot be reinfected (Fu, Chen, and Wang [@CR7]). Also, some people might have false positive tests for SARS-CoV-2 antibodies and have zero protection against their first infection (Ismail [@CR8]). Conversely, another potential situation which has been observed is patients have prior tested positive for SARS-CoV-2 RNA (active infection with or without symptoms) and yet test negative for SARS-CoV-2 antibodies (Centers for Disease Control and Prevention [@CR5]). Those with negative antibody test results could use various forms of identity theft to confer themselves a positive test result.

Even if a positive result were scientifically confirmed to confer immunity, there would be the additional matter of a validity date/expiration date. Also, there is the matter of creating a globally recognized standard for certification \[test method, titres\], robust certification agencies, and the logistical issues of documentation language so that certificates could be readable across countries.

Preventing a Caste System {#Sec3}
=========================

Attempting to rescue the economy with a scientifically unproven antibody passport is problematic for many reasons, including a false sense of health security. But if a COVID-19 antibody passport *could* be scientifically validated and distributed via a system with globalized recognition, there is the potential for a caste system to result; namely the haves and the have nots of "golden passports." Those holding such a passport could benefit from work and movement rights similar to the rights generated by customary immigration visas and passports. Systems to prevent fraud with the antibody passport could be implemented using biometrics; however, there could remain a group of people for whom work and travel could have restrictions. This could create a coercion for people to intentionally expose themselves to the virus (Kates [@CR9]) in order to "earn" a passport that could provide them valuable privileges.

Ethically, work and travel restrictions are appropriate for people who are actively infected. Work and travel restrictions could also be appropriate for others as well, but care must be taken to not psychologically or otherwise damage those who are "not immune" from COVID-19. Stigma as well as other harms could potentially negatively impact a person's employability, promotability, insurance rates, access to housing, etc. These ethical concerns heighten the need for policy advisors to reflect beyond the science when they consider enacting antibody passports.

In the future there might be a call for COVID-19 vaccination certificates (Phelan [@CR13]); however, this too will generate legal and ethical debate. There will be issues of cost, access, safety, and consent, but also many facets of the current antibody issue will be present as well; namely, antibody titres, re-infectivity, and expiry/boosters. The ethical call is to proactively reflect on these antibody-related matters to create systems which are clinically safe and fraud resistant and avoid discrimination.
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